JP6302895B2 - 親和性リガンドとして免疫グロブリン断片を組み込んだクモ糸融合タンパク質の構造 - Google Patents

親和性リガンドとして免疫グロブリン断片を組み込んだクモ糸融合タンパク質の構造 Download PDF

Info

Publication number
JP6302895B2
JP6302895B2 JP2015509440A JP2015509440A JP6302895B2 JP 6302895 B2 JP6302895 B2 JP 6302895B2 JP 2015509440 A JP2015509440 A JP 2015509440A JP 2015509440 A JP2015509440 A JP 2015509440A JP 6302895 B2 JP6302895 B2 JP 6302895B2
Authority
JP
Japan
Prior art keywords
protein
amino acid
fusion protein
acid residues
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015509440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518489A5 (enExample
JP2015518489A (ja
Inventor
ミュー ヘドハンマル，
ミュー ヘドハンマル，
ヤーン ヨハンソン，
ヤーン ヨハンソン，
アンナ ライジング，
アンナ ライジング，
ペル−オーケ ニーグレン，
ペル−オーケ ニーグレン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spiber Technologies AB
Original Assignee
Spiber Technologies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spiber Technologies AB filed Critical Spiber Technologies AB
Publication of JP2015518489A publication Critical patent/JP2015518489A/ja
Publication of JP2015518489A5 publication Critical patent/JP2015518489A5/ja
Application granted granted Critical
Publication of JP6302895B2 publication Critical patent/JP6302895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015509440A 2012-05-02 2013-05-02 親和性リガンドとして免疫グロブリン断片を組み込んだクモ糸融合タンパク質の構造 Active JP6302895B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12166392.6 2012-05-02
EP12166392 2012-05-02
PCT/EP2013/059145 WO2013164404A1 (en) 2012-05-02 2013-05-02 Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands

Publications (3)

Publication Number Publication Date
JP2015518489A JP2015518489A (ja) 2015-07-02
JP2015518489A5 JP2015518489A5 (enExample) 2016-06-23
JP6302895B2 true JP6302895B2 (ja) 2018-03-28

Family

ID=48468238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509440A Active JP6302895B2 (ja) 2012-05-02 2013-05-02 親和性リガンドとして免疫グロブリン断片を組み込んだクモ糸融合タンパク質の構造

Country Status (6)

Country Link
US (1) US9856308B2 (enExample)
EP (1) EP2844361B1 (enExample)
JP (1) JP6302895B2 (enExample)
CN (1) CN104470607B (enExample)
CA (1) CA2872305A1 (enExample)
WO (1) WO2013164404A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434764B1 (en) 2009-12-09 2026-04-08 The Procter & Gamble Company Fabric and home care products
CN104877031B (zh) * 2015-05-23 2019-04-23 浙江省农业科学院 一种新型融合蛋白nscr5及其制备方法
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017188346A1 (ja) * 2016-04-27 2017-11-02 国立大学法人 東京大学 マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法
EP3263593A1 (en) 2016-07-01 2018-01-03 Anna Rising Engineered spider silk proteins and uses thereof
JPWO2020158947A1 (ja) * 2019-01-31 2021-12-02 Ｓｐｉｂｅｒ株式会社 ポリペプチド
EP4062934A4 (en) * 2019-11-18 2024-03-20 CentricsBio, Inc. COMPOSITION FOR PREVENTING OR TREATING CANCER WITH ANTI-CD300C MONOCLONAL ANTIBODIES
CN117756926B (zh) * 2023-12-26 2024-06-07 广东普言生物科技有限公司 一种重组ⅩⅦ型胶原蛋白Pro.C17及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0704532B1 (en) 1994-06-10 2002-09-11 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
JP2000125872A (ja) 1998-09-07 2000-05-09 Terumo Corp 三量体キメラタンパク質およびキメラタンパク質を含有するコラーゲンマトリックス
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20050261479A1 (en) 2004-04-29 2005-11-24 Christian Hoffmann Method for purifying and recovering silk proteins using magnetic affinity separation
WO2006076711A2 (en) 2005-01-14 2006-07-20 Trustees Of Tufts College Fibrous protein fusions and use thereof in the formation of advanced organic/inorganic composite materials
RU2444527C2 (ru) * 2005-12-30 2012-03-10 Спибер Текнолоджиз Аб Рекомбинантный спидроиновый белок главной ампулярной железы, способный к полимеризации, рекомбинантный слитый белок, способный к управляемой полимеризации, полимер спидроинового белка главной ампулярной железы, композиция для управляемой полимеризации, рекомбинантная молекула нуклеиновой кислоты (варианты), способ получения растворимого слитого белка, способ получения полимера спидроинового белка главной ампулярной железы и способ культивирования эукариотических клеток
EP1852470A1 (en) 2006-05-03 2007-11-07 Technische Universität München Multilayer Silk Protein Films
WO2009069123A2 (en) * 2007-11-26 2009-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions comprising fibrous polypeptides and polysaccharides
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CN103270049B (zh) * 2010-10-27 2017-10-13 思百博技术股份公司 用于结合有机靶的蜘蛛丝融合蛋白结构

Also Published As

Publication number Publication date
CN104470607A (zh) 2015-03-25
EP2844361A1 (en) 2015-03-11
US20150119554A1 (en) 2015-04-30
CN104470607B (zh) 2017-04-05
JP2015518489A (ja) 2015-07-02
EP2844361B1 (en) 2020-03-25
WO2013164404A1 (en) 2013-11-07
US9856308B2 (en) 2018-01-02
CA2872305A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
JP6057904B2 (ja) 有機ターゲットに結合するためのクモ糸融合タンパク質構造
US9856308B2 (en) Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands
JP6412866B2 (ja) 有機ターゲットに結合するための反復断片を持たないクモ糸融合タンパク質の構造
JP5655254B2 (ja) ポリカーボネートおよび／またはポリメタクリル酸メチル親和性ペプチド、およびその利用
CN112625111B (zh) 突触囊泡蛋白sv2a的制备方法
JP6818305B2 (ja) 非天然型立体構造を形成した抗体に親和性を示すポリペプチド
AU2020253470A1 (en) Functionalized Ubx protein materials for enhanced purification of antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180305

R150 Certificate of patent or registration of utility model

Ref document number: 6302895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250